Treatment of multiple sclerosis in children and adolescents (Q37693918)

22 August 2017

1 reference

title

Treatment of multiple sclerosis in children and adolescents (English)

1 reference

22 August 2017

0 references

1 reference

8

1 reference

22 August 2017

Emmanuelle Waubant

9

1 reference

22 August 2017

Bianca Weinstock-Guttman

3

object named as

Bianca Weinstock-Guttman

1 reference

22 August 2017

4

Tanuja Chitnis

1 reference

22 August 2017

Nancy L Kuntz

1

1 reference

22 August 2017

Dorothee Chabas

2

1 reference

22 August 2017

E Ann Yeh

5

1 reference

22 August 2017

Lauren Krupp

6

1 reference

22 August 2017

Jayne Ness

7

1 reference

22 August 2017

Network of US Pediatric Multiple Sclerosis Centers

10

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

505-520

1 reference

Consensus definitions proposed for pediatric multiple sclerosis and related disorders

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Italian studies on early-onset multiple sclerosis: the present and the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Corticosteroids treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

In vivo glucocorticoid modulation of guinea pig splenic macrophage Fc gamma receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Steroids and brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Acute disseminated encephalomyelitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Treatment of children and adolescents with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Risks associated with the use of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Childhood multiple sclerosis treated with plasmapheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Treatment of pediatric multiple sclerosis and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Treatment of Pediatric Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Cyclophosphamide therapy in pediatric multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Acute ovarian failure in the childhood cancer survivor study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Ovarian function following the treatment of childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Mycophenolate mofetil in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Combination therapies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

New oral drugs for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Oral laquinimod therapy in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Natural history of multiple sclerosis with childhood onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Spasticity management: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Pharmacotherapy of spasticity: oral medications and intrathecal baclofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Pharmacologic interventions for reducing spasticity in cerebral palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Use of modafinil in spastic cerebral palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Sustained-release fampridine for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Sustained release oral fampridine in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Thalamic stimulation in patients with multiple sclerosis: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

The cognitive burden of multiple sclerosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Donepezil improved memory in multiple sclerosis in a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Bladder Dysfunction and Management in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Benign course in multiple sclerosis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656560903527218

10.1517/14656560903527218

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference